We therefore strongly recommend to determine serum tryptase and KIT D816 mutation status in all AML patients, and to perform bone marrow histology in KIT D816mut patients. These simple diagnostic measures would allow reclassification to SM-AML and inclusion of KIT inhibitors in establi...
KIT D816V D816V是一种在急性髓细胞白血病(AML)中观察到的突变。这种变异与AML患者预后差和预后差有关。KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients....
D579_H580insIDPTQLPYD D816E S628N 3' UTR MUTATION W557_K558DELWK D579DEL T670I T417_D419delinsY EXON 13 MUTATION V555_V559DEL KIT 基因突变D816H Allele Registry ID:CA123540别名:ASP816HIS,RS121913506 ClinVar ID:13863 基因突变位点 ...
V555_I571DEL K550_W557delKPMYEVQW T417_D419DELTYDINSI D579_H580insIDPTQLPYD D816E S628N 3' UTR MUTATION W557_K558DELWK D579DEL T670I T417_D419delinsY EXON 13 MUTATION V555_V559DELKIT 基因突变 D816YAllele Registry ID:CA280196别名:RS121913506 ClinVar ID:13860基因突变位点 ...
D579_H580insIDPTQLPYD D816E S628N 3' UTR MUTATION W557_K558DELWK D579DEL T670I T417_D419delinsY EXON 13 MUTATION V555_V559DEL KIT 基因突变 D816E Allele Registry ID:CA356911882别名:D812E ClinVar ID: 基因突变位点 Ref. Build: GRCh37 Ensembl Version: 75 Chr. Start Stop Ref. s ...
目前,已有多项案例报道和回顾性研究探讨了阿伐替尼在KIT突变AML患者中的应用情况。陈苏宁教授的病例报道5显示,四例伴有KIT D816突变的CBF-AML患者在接受阿伐替尼治疗后均获得良好的临床缓解,且未观察到严重的不良事件。这一结果提示阿...
维持期显著相关,是伴t(8;21)aml复发后cr 2 率的不良影响因素,可以作为其挽救治疗疗效的预测指标.kit d816突变对伴t(8;21)复发aml治疗方案的选择有一定的指导意义. 关键词: 突变; 基因,kit; 白血病,髓样,急性; 复发; 预后 abstract objective to evaluate the impact of kit d816 mutation on the salvage...
February 2016,Vol 51,No2 C—KIT—D81 6V、NPM 1基 因突变在急性髓系 白血病 中的临床 意义 ★ 熊丽芳 ,李萍 ,张荣艳 (1、南昌大学第三附属医院血液科,南昌 330006;2、南昌大学第一附属医院血液科,南昌 330006) · 实验研 究· 摘要:目的 探讨 C—KIT—D816V、NPM1与AML患者临床特征、疗效及预后相关...
[摘要] 目的 探讨侵袭性系统性肥大细胞增生症伴K I T D 816V 突变的临床特点㊁ 诊治方法和经验㊂方法报告1例侵袭性系统性肥大细胞增生症伴K I T D 816V 突变病人临床资料,并复习相关文献,总结其病因㊁临床特点㊁诊治经过及治疗经验㊂结果 病人经伊马替尼及阿伐替尼治疗后症状稍有改善㊂结论 侵袭性...
The c-kit D816V activating mutation is found in >80% of cases of systemic mastocytosis (SM) and represents a potential drug target. Furthermore, because D816V is one of the diagnostic criteria for SM, it is clinically relevant to determine whether the mutation is present. Traditional techni...